Search

Your search keyword '"Proscar (Medication) -- Research"' showing total 21 results
Start Over Descriptor "Proscar (Medication) -- Research"
21 results on '"Proscar (Medication) -- Research"'

1. WARDING OFF PROSTATE CANCER

Author

Roman, Monica

Subjects
Merck & Company Inc. -- Product information, United States. National Cancer Institute -- Research, Proscar (Medication) -- Research, Pharmaceutical industry -- Product information, Prostate cancer -- Drug therapy, Prostate cancer -- Prevention
Published
2003

2. Common Drug for Prostrate Is Ineffective, Study Finds

Author

Altman, Lawrence K.

Subjects
Merck & Company Inc., Abbott Laboratories (Abbott Park, Illinois), Hytrin (Medication) -- Research, Proscar (Medication) -- Research, Pharmaceutical industry -- Research
Abstract

The first direct comparison of two main drugs approved for treating an enlarged prostate gland, a common condition in older men, has shown that one is no better than a […]

Published
1996

3. Study finds Abbott's prostate drug is much more effective than Merck's

Author

Winslow, Ron

Subjects
Abbott Laboratories (Abbott Park, Illinois) -- Research -- 00300025, Merck & Company Inc. -- Research -- 00305661, Prostate diseases -- Drug therapy, Pharmaceutical industry -- Research, Terazosin hydrochloride -- Research, Business, Business, general, Proscar (Medication) -- Research, Hytrin (Medication) -- Research
Published
1996

4. Merck to study new BPH drug for other benefits

Author

Starr, Cynthia

Subjects
Merck Sharp and Dohme -- Product information, Proscar (Medication) -- Research, Prostate -- Hypertrophy, Pharmaceutical industry -- Product information
Abstract

Proscar, a new drug for the treatment of benign prostatic hyperplasia, will be available for the first time in the US in July. Research shows that the drug works by inhibiting 5-alpha reductase, the enzyme responsible for converting testosterone to dihydrotestosterone (DHC). DHC is the hormone that has been implicated in prostate enlargement. Early clinical trials have been promising. In one study, 50% of test subjects experienced a gland shrinkage of 20% or more. There is also evidence that the drug might prevent hair loss., The first drug approved for the treatment of benign prostatic hyperplasia becomes available to American men this month. Merck Sharp & Dohme, maker of Proscar (finasteride), estimates that some 10 [...]

Published
1992

8. Two-for-one prostate protection

Author

Good, Brian

Subjects
Proscar (Medication) -- Research, Prostate cancer -- Drug therapy
Abstract

Proscar, a medication for treating enlarged prostates, could be a new tool in the fight against prostate cancer. Researchers are close to completing a 7-year study of 18,000 men to [...]

Published
2003

9. Large-scale trial establishes benefits of long-term management of prostate disease (PART III OF V)

Subjects
Merck & Company Inc. -- Product development -- 00305661, Pharmaceutical industry -- Product development, Business, Business, international, Proscar (Medication) -- Research
Abstract

WEST POINT, Pa.--(BUSINESS WIRE)--Nov. 1, 1995-- -0- Clinical Studies Patients with BPH were treated with either PROSCAR 5 mg/day or placebo in North American and international multicenter, double-blind, 12-month studies [...]

Published
1995

10. Large-scale trial establishes benefits of long-term management of prostate disease (PART V OF V)

Subjects
Merck & Company Inc. -- Product development -- 00305661, Pharmaceutical industry -- Product development, Business, Business, international, Proscar (Medication) -- Research
Abstract

WEST POINT, Pa.--(BUSINESS WIRE)--Nov. 1, 1995-- -0- Pregnancy Pregnancy Category X See CONTRAINDICATIONS. PROSCAR is not indicated for use in women. Administration of finasteride to pregnant rats at doses ranging [...]

Published
1995

11. Large-scale trial establishes benefits of long-term management of prostate disease (PART IV OF V)

Subjects
Merck & Company Inc. -- Product development -- 00305661, Pharmaceutical industry -- Product development, Business, Business, international, Proscar (Medication) -- Research
Abstract

WEST POINT, Pa.--(BUSINESS WIRE)--Nov. 1, 1995-- -0- PRECAUTIONS General Digital rectal examinations, as well as other evaluations for prostate cancer, should be performed on patients with BPH prior to initiating [...]

Published
1995

12. Large-scale trial establishes benefits of long-term management of prostate disease (PART II OF V)

Subjects
Merck & Company Inc. -- Product development -- 00305661, Pharmaceutical industry -- Product development, Business, Business, international, Proscar (Medication) -- Research
Abstract

WEST POINT, Pa.--(BUSINESS WIRE)--Nov. 1, 1995-- -0- PROSCAR(R) (FINASTERIDE) TABLETS DESCRIPTION PROSCAR(a) (finasteride), a synthetic 4-azasteroid compound, is a specific inhibitor of steroid 5a-reductase, an intracellular enzyme that converts testosterone [...]

Published
1995

13. Large-scale trial establishes benefits of long-term management of prostate disease (PART I OF V)

Subjects
Merck & Company Inc. -- Product development -- 00305661, Pharmaceutical industry -- Product development, Business, Business, international, Proscar (Medication) -- Research
Abstract

WEST POINT, Pa.--(BUSINESS WIRE)--Nov. 1, 1995--The first two-year, placebo-controlled clinical evaluation of medical therapy for the treatment of benign prostatic hyperplasia (BPH) found that Proscar relieves urinary symptoms and appears [...]

Published
1995

14. Massive study launched on prostate cancer

Author

Burling, Stacey

Subjects
United States. National Cancer Institute -- Research, Proscar (Medication) -- Research, Prostate cancer -- Research, Hospitals -- Research
Abstract

The National Cancer Institute and 222 U.S. hospitals Wednesday launched a massive, 10-year study aimed at preventing prostate cancer _ a disease that affects more than one-third of men over […]

Published
1993

15. Proscar link to breast cancer debated

Subjects
United States. Food and Drug Administration -- Research, Merck & Company Inc. -- Research -- 00305661, Pharmaceutical industry -- Research, Business, Pharmaceuticals and cosmetics industries, Proscar (Medication) -- Research
Published
1996

16. US finasteride/doxazosin trial in BPH

Subjects
Merck & Company Inc. -- Product information -- 00305661, Pharmaceutical industry -- Product information, Prostate -- Hypertrophy, Adrenergic alpha blockers -- Research, Business, Pharmaceuticals and cosmetics industries, Proscar (Medication) -- Research, Cardura (Medication) -- Research
Published
1995

17. Merck's plans for Proscar

Subjects
Merck & Company Inc. -- Product development, Pharmaceutical industry -- Product development, Business, Pharmaceuticals and cosmetics industries, Proscar (Medication) -- Research
Published
1994

18. Proscar in male pattern baldness

Subjects
Merck & Company Inc. -- Research, Pharmaceutical industry -- Research, Baldness -- Care and treatment, Business, Pharmaceuticals and cosmetics industries, Proscar (Medication) -- Research
Published
1994

19. New Proscar/Hytrin study in BPH

Subjects
United States. Department of Veterans Affairs -- Research, United States. Department of Veterans Affairs -- Finance, Merck & Company Inc. -- Finance, Abbott Laboratories (Abbott Park, Illinois) -- Finance, Prostate -- Hypertrophy, Pharmaceutical industry -- Finance, Business, Pharmaceuticals and cosmetics industries, Proscar (Medication) -- Research, Hytrin (Medication) -- Research
Published
1993

20. Finisteride/doxazosin no better than placebo for urinary obstruction

Author

Elliott, William T.

Subjects
Pharmaceutical industry -- Research, Family and marriage, Health, Proscar (Medication) -- Research
Abstract

Finisteride (Proscar) is no better than placebo when used in combination with doxazosin for the treatment of urinary obstruction due to benign prostatic hypertrophy, according to the recently published Prospective [...]

Published
2003

Catalog

Books, media, physical & digital resources
See catalog results